• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Can long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Bleehen, N M
    Girling, D J
    Gregor, A
    Leonard, R C
    Machin, D
    McKenzie, C G
    Morgan, D A
    Smyth, J F
    Spittle, M F
    Stephens, R J
    Thatcher, Nick
    Show allShow less
    Affiliation
    MRC Clinical Oncology and Radiotherapeutics Unit, Addenbrooke's Hospital, Cambridge, UK.
    Issue Date
    1994-07
    
    Metadata
    Show full item record
    Abstract
    Results from a long-term follow-up suggest that in patients with limited small-cell lung cancer (SCLC) and normal performance status intensive alternating chemotherapy and radiotherapy improve long-term survival rates. In a non-randomised study, 22 patients with SCLC of limited extent and good performance status were prescribed six cycles of etoposide, doxorubicin, cisplatin and cyclophosphamide at 4 week intervals with doses of thoracic radiotherapy following the second, third and fourth cycles. Although only six patients received all their prescribed treatment, nine (41%) were alive at 1 year, seven (32%) at 2 years, six (27%) at 3 years, and four are still alive at, respectively, 42, 47, 50, and 61 months, all four being in the subgroup of eight patients with WHO performance status grade 0 at the start of treatment. In a comparison with similar patients receiving conventionally scheduled chemotherapy and radiotherapy in a concurrent trial, no difference in survival was seen in the patients with performance status grade 1 or 2, but a large difference in favour of the alternating schedule in those with grade 0 status was seen. We encourage other investigators to report the results achieved with intensive treatment in patients with WHO grade 0 performance status at the start of treatment.
    Citation
    Can long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party. 1994, 70 (1):142-4 Br. J. Cancer
    Journal
    British Journal of Cancer
    URI
    http://hdl.handle.net/10541/108699
    PubMed ID
    8018526
    Type
    Article
    Language
    en
    ISSN
    0007-0920
    Collections
    All Christie Publications

    entitlement

    Related articles

    • [Small cell lung carcinoma: role of thoracic irradiation and its timing in relation to chemotherapy].
    • Authors: Payne DG, Murray N, Warde P
    • Issue date: 1994 Feb
    • Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin-etoposide for limited-stage small-cell carcinoma of the lung.
    • Authors: Murray N, Shah A, Brown E, Kostashuk E, Laukkanen E, Goldie J, Band P, Van den Hoek J, Murphy K, Sparling T
    • Issue date: 1986 Sep
    • Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study.
    • Authors: Gregor A, Drings P, Burghouts J, Postmus PE, Morgan D, Sahmoud T, Kirkpatrick A, Dalesio O, Giaccone G
    • Issue date: 1997 Aug
    • Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    • Authors: Ardizzoni A, Fusco V, Pennucci C, Baldini E, Orsatti M, Vitale V, Bonavia M, Baracco F, Mereu C, Rosso R
    • Issue date: 1991 Mar-Apr
    • A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
    • Authors: Bleehen NM, Girling DJ, Machin D, Stephens RJ
    • Issue date: 1993 Dec
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.